Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
The drug demonstrates improvements in overall survival and progression-free survival, but not enough for success in KEYNOTE-240.
Galera garnered $70m in Series C venture capital and $80m through a royalty deal tied to GC4419 and a follow-up drug for the treatment of severe oral mucositis caused by radiation therapy with an initial focus on head and neck cancer patients.
Sanofi completes the transition of its infectious disease unit to Evotec. Perhaps not yet done with virology, Gilead licenses technology for HIV/hep B vaccines from Hookipa.